Description:
The purpose of this clinical trial is to test whether treatment of patients with advanced or
metastatic solid tumors or breast cancer with Abraxane plus Vidaza is safe and results in
good tumor response. All patients enrolling in this study will receive treatment with
Abraxane and Vidaza. Safety will be assessed by adverse events, laboratory results and
performance status. Tumor response will be measured by RECIST criteria.
Title
- Brief Title: A Phase I/II Clinical Trial of Vidaza With Abraxane in Patients With Advanced/Metastatic Solid Tumors and Breast Cancer
- Official Title: A Phase I/II Clinical Trial of the Hypomethylating Agent Azacitidine (Vidaza) With the Nanoparticle Albumin Bound Paclitaxel (Abraxane) in the Treatment of Patients With Advanced or Metastatic Solid Tumors and Breast Cancer
Clinical Trial IDs
- ORG STUDY ID:
HCI53993
- NCT ID:
NCT00748553
Conditions
- Advanced or Metastatic Solid Tumors
- Advanced or Metastatic Breast Cancer
Interventions
Drug | Synonyms | Arms |
---|
Azacitidine (Vidaza) | Vidaza | All patients |
Nab-paclitaxel (Abraxane) | Abraxane | All patients |
Purpose
The purpose of this clinical trial is to test whether treatment of patients with advanced or
metastatic solid tumors or breast cancer with Abraxane plus Vidaza is safe and results in
good tumor response. All patients enrolling in this study will receive treatment with
Abraxane and Vidaza. Safety will be assessed by adverse events, laboratory results and
performance status. Tumor response will be measured by RECIST criteria.
Detailed Description
The phase I part of the study will enroll patients with advanced or metastatic solid tumors
who have failed at least one previous treatment. The purpose of the phase I part is to assess
the safety of the investigational treatment and select the recommended phase II dose-regimen.
The phase II part of the study will enroll patients with advanced or metastatic HER2-negative
breast cancer who have not received treatment for their metastatic disease. The purpose of
the phase II part of the study is to assess safety and efficacy of the investigational
treatment in breast cancer. The study doctor will determine what phase patients will be
enrolled in.
Trial Arms
Name | Type | Description | Interventions |
---|
All patients | Experimental | All participants enrolled. | - Azacitidine (Vidaza)
- Nab-paclitaxel (Abraxane)
|
Eligibility Criteria
Inclusion Criteria:
1. For phase I, any solid tumors, including lymphoma, that progressed or were stable as
best response on at least one previous therapy and are evaluable.
2. For phase II, pathologically confirmed breast cancer, measurable disease, no prior
treatments for recurrent or metastatic breast cancer.
3. Her-2/neu negative (Phase II)
4. Negative pregnancy test for female subjects
5. Women of childbearing potential should be advised to avoid becoming pregnant and men
should be advised to not father a child while receiving treatment with azacitidine or
nab-paclitaxel. investigator.
6. Male or female for phase I and female for phase II, >19 years of age and any race.
Exclusion Criteria:
1. Major surgery, radiotherapy, chemotherapy or investigational agents within 4 weeks of
treatment day 1
2. Known brain metastases
3. Prior taxanes (except for adjuvant therapy more than 6 months prior to treatment day
1) (phase II)
4. Active infection requiring antibiotic therapy
5. History of allergy or hypersensitivity to nab-paclitaxel, albumin or a taxane
6. Grade 2 or greater motor or sensory neuropathy
7. Prior cytotoxic chemotherapy for recurrent or metastatic breast cancer (phase II
portion)
8. Uncontrolled hypertension, arrhythmia, congestive heart failure or angina. Patients
who have had a myocardial infarction or cardiac surgery should be at least 6 months
from the event and free of active symptoms.
9. Known or suspected hypersensitivity to azacitidine or mannitol
10. Pregnant or breast feeding
11. Patients with advanced malignant hepatic tumors
12. Malignancy other than breast carcinoma (phase II)
13. Known HIV infection or chronic hepatitis B or C
Maximum Eligible Age: | N/A |
Minimum Eligible Age: | 18 Years |
Eligible Gender: | All |
Healthy Volunteers: | No |
Primary Outcome Measures
Measure: | Phase I: Percentage of Participants Responding to Treatment |
Time Frame: | 6 months |
Safety Issue: | |
Description: | Azacitidine is set at 75mg/m2 and Nab-paclitaxel is set at100mg/m2 based on the number of participants responding to treatment as measured per RECIST v1 criteria. |
Secondary Outcome Measures
Measure: | Number of Participants With ER+ Status |
Time Frame: | 2 years |
Safety Issue: | |
Description: | Tissue SPARC protein will be assessed using archival tumor blocks. In addition, in patients who have easily accessible tumors, such as lymph nodes, cutaneous or subcutaneous lesions, and who have consented to sample collection, biopsies will be taken twice: before cycle 1 day 1 treatment, and cycle 3 day 8 (+/- 3 days). |
Measure: | Progression-free Survival |
Time Frame: | 2 years |
Safety Issue: | |
Description: | Progression-free survival (PSF) is defined as the length of time during and after treatment in which a patient is living with a disease that does not get worse. |
Details
Phase: | Phase 1/Phase 2 |
Primary Purpose: | Interventional |
Overall Status: | Completed |
Lead Sponsor: | University of Utah |
Last Updated
July 26, 2017